Primary tumor surgery in patients with de novo stage IV breast cancer: Is there an optimal subgroup for locoregional therapy?
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
165 patients, metastatic burden ranged from 40.
I · Intervention 중재 / 시술
therapy at a distant metastatic site
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
LRT receipt at metastatic site did not impact survival outcomes. [CONCLUSIONS] Long-term survival can be achieved in select patients with de novo stage IV breast cancer treated with multimodal therapy.
[BACKGROUND] Surgery remains controversial in de novo stage IV breast cancer.
APA
Chen JH, Yang Z, et al. (2026). Primary tumor surgery in patients with de novo stage IV breast cancer: Is there an optimal subgroup for locoregional therapy?. American journal of surgery, 251, 116700. https://doi.org/10.1016/j.amjsurg.2025.116700
MLA
Chen JH, et al.. "Primary tumor surgery in patients with de novo stage IV breast cancer: Is there an optimal subgroup for locoregional therapy?." American journal of surgery, vol. 251, 2026, pp. 116700.
PMID
41197203 ↗
Abstract 한글 요약
[BACKGROUND] Surgery remains controversial in de novo stage IV breast cancer. We examined differential impact of surgery on survival outcomes among a surgical cohort of stage IV patients.
[METHODS] We retrospectively reviewed stage IV patients treated with surgery (2014-2022) and evaluated impact of metastatic disease burden and site on survival outcomes. LRT receipt at metastatic site included surgical resection, ablation, and/or radiation therapy.
[RESULTS] Of 165 patients, metastatic burden ranged from 40.0 % (66) solitary [1 lesion], 32.7 % (54) oligometastatic [2-3 lesions], and 27.3 % (45) multiple [≥4 lesions]. Metastatic site consisted of 38.2 % (63) bone-only, 25.5 % (42) soft tissue/lymph node, and 36.4 % (60) visceral. 67.9 % (112) received therapy at a distant metastatic site. Triple negative subtype and multiple metastatic lesions were poor prognostic factors while soft tissue/lymph node involvement was associated with improved prognosis. LRT receipt at metastatic site did not impact survival outcomes.
[CONCLUSIONS] Long-term survival can be achieved in select patients with de novo stage IV breast cancer treated with multimodal therapy.
[METHODS] We retrospectively reviewed stage IV patients treated with surgery (2014-2022) and evaluated impact of metastatic disease burden and site on survival outcomes. LRT receipt at metastatic site included surgical resection, ablation, and/or radiation therapy.
[RESULTS] Of 165 patients, metastatic burden ranged from 40.0 % (66) solitary [1 lesion], 32.7 % (54) oligometastatic [2-3 lesions], and 27.3 % (45) multiple [≥4 lesions]. Metastatic site consisted of 38.2 % (63) bone-only, 25.5 % (42) soft tissue/lymph node, and 36.4 % (60) visceral. 67.9 % (112) received therapy at a distant metastatic site. Triple negative subtype and multiple metastatic lesions were poor prognostic factors while soft tissue/lymph node involvement was associated with improved prognosis. LRT receipt at metastatic site did not impact survival outcomes.
[CONCLUSIONS] Long-term survival can be achieved in select patients with de novo stage IV breast cancer treated with multimodal therapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- ASO Visual Abstract: Implications for Sentinel Lymph Node Biopsy Omission in Patients with Early Stage Node-Negative HR+/HER2- Breast Cancer Undergoing Mastectomy.
- CCR7 immune cell receptor expression in inflammatory breast cancer.
- Implications for Sentinel Lymph Node Biopsy Omission in Patients with Early-Stage Node-Negative HR+/HER2- Breast Cancer Undergoing Mastectomy.
- Tumor Size as a Predictive Indicator for Lymph Node Metastasis in Papillary Thyroid Carcinoma: An Inverted L-Shaped Curve Analysis Based on the SEER Database.
- Combination Assay of Methylated HOXA1 with Tumor Markers for Detection of Early-Stage Hepatocellular Carcinoma.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.